4//SEC Filing
Davidson Michael H. 4
Accession 0001654954-24-015472
CIK 0000034956other
Filed
Dec 11, 7:00 PM ET
Accepted
Dec 12, 7:54 PM ET
Size
11.3 KB
Accession
0001654954-24-015472
Insider Transaction Report
Form 4
Davidson Michael H.
Director
Transactions
- Award
Stock Option (right to buy)
2024-12-10+100,000→ 100,000 totalExercise: $5.94From: 2025-12-10Exp: 2034-12-10→ Common Stock (100,000 underlying)
Holdings
- 4
Stock Option (right to buy)
Exercise: $3200.00From: 2022-06-10Exp: 2031-06-10→ Common Stock (4 underlying) - 2,881
Common Stock
- 47,500
Pre-Funded Warrant
Exercise: $0.01From: 2024-08-08→ Common Stock (47,500 underlying) - 4
Stock Option (right to buy)
Exercise: $992.00From: 2023-06-09Exp: 2032-06-09→ Common Stock (4 underlying) - 25,000
Warrant
Exercise: $4.50From: 2024-08-08→ Common Stock (25,000 underlying)
Footnotes (2)
- [F1]The pre-funded warrant has no expiration date.
- [F2]The warrant will expire on the earlier of (i) thirty (30) trading days following the date of the Issuer's initial public announcement of topline data from its Phase 3 LEVEL Study (LEVosimendan to Improve Exercise Limitation in PH-HFpEF Patients) ( NCT05983250 ) (the "Topline Data Announcement"); (ii) proportionally upon the exercise of the Reporting Person's pre-funded warrant issued on August 8, 2024, if such exercise is prior to the Topline Data Announcement; and (iii) August 8, 2029.
Documents
Issuer
TENAX THERAPEUTICS, INC.
CIK 0000034956
Entity typeother
Related Parties
1- filerCIK 0001573785
Filing Metadata
- Form type
- 4
- Filed
- Dec 11, 7:00 PM ET
- Accepted
- Dec 12, 7:54 PM ET
- Size
- 11.3 KB